EP Patent

EP2347762A1 — Exendin for treating diabetes and reducing body weight

Assigned to Amylin Pharmaceuticals LLC · Expires 2011-07-27 · 15y expired

What this patent protects

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA 1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

USPTO Abstract

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA 1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

Drugs covered by this patent

Patent Metadata

Patent number: EP2347762A1
Jurisdiction: EP
Classification: —
Expires: 2011-07-27
Drug substance claim: No
Drug product claim: No
Assignee: Amylin Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.